Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].

Li ZL, Chen X, Xia CC, Sun JY, Li CX, Tang HH, Song B.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;43(4):601-4. Chinese.

PMID:
22997905
2.
3.

Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.

Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, Tanaka H, Nakayama T, Morikawa T, Breuer J, Aitoku Y.

Invest Radiol. 2011 Jul;46(7):411-8. doi: 10.1097/RLI.0b013e3182145a6c.

PMID:
21467949
4.

Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine.

Kim ES, Chang JH, Choi HS, Kim J, Lee SK.

AJNR Am J Neuroradiol. 2010 Jun;31(6):1055-8. doi: 10.3174/ajnr.A2010. Epub 2010 Jan 28.

5.

[Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].

Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R.

Radiologe. 1995 Aug;35(8):508-16. German.

PMID:
7568795
6.

Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.

Huang B, Liang CH, Liu HJ, Wang GY, Zhang SX.

Acta Radiol. 2010 Feb;51(1):78-84. doi: 10.3109/02841850903350178.

PMID:
19912078
7.

Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.

Thilmann O, Larsson EM, Björkman-Burtscher IM, Ståhlberg F, Wirestam R.

J Magn Reson Imaging. 2005 Nov;22(5):597-604.

PMID:
16200539
8.

Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Seidl Z, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, Pasowicz M, Yeung R, Paraniak-Gieszczyk B, Yemen B, Anzalone N, Citterio A, Schneider G, Bastianello S, Ruscalleda J.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1050-8. doi: 10.3174/ajnr.A3033. Epub 2012 Mar 1.

9.

MultiHance in the assessment of intracranial tumors: results of phase II clinical studies.

Ruscalleda J, Kirchin MA, La Noce A, Pirovano G, Spinazzi A.

J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S19-27.

PMID:
10608394
10.

Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.

Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI.

Invest Radiol. 2010 Dec;45(12):810-8. doi: 10.1097/RLI.0b013e3181f03d8a.

PMID:
20856127
11.

Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography.

Herborn CU, Lauenstein TC, Ruehm SG, Bosk S, Debatin JF, Goyen M.

Invest Radiol. 2003 Jan;38(1):27-33.

PMID:
12496518
12.

Detectability of small liver metastases with gadolinium BOPTA.

Runge VM, Lee C, Williams NM.

Invest Radiol. 1997 Sep;32(9):557-65.

PMID:
9291044
13.

Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.

Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB.

Eur J Radiol. 2008 Apr;66(1):65-74. Epub 2007 Jun 6.

PMID:
17555901
14.

Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol.

Jeon JY, Choi JW, Roh HG, Moon WJ.

Korean J Radiol. 2014 Jan-Feb;15(1):145-50. doi: 10.3348/kjr.2014.15.1.145. Epub 2014 Jan 8.

15.

Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.

Anzalone N, Gerevini S, Scotti R, Vezzulli P, Picozzi P.

Acta Radiol. 2009 Oct;50(8):933-40. doi: 10.1080/02841850903095385.

PMID:
19626475
16.

Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.

Fan B, Li M, Wang X, Xu Y, Li F, Zhang L, Jiang J, Jiang Y.

J Magn Reson Imaging. 2017 Jun;45(6):1827-1834. doi: 10.1002/jmri.25491. Epub 2016 Oct 3.

PMID:
27696616
17.

Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.

Giesel FL, Mehndiratta A, Risse F, Rius M, Zechmann CM, von Tengg-Kobligk H, Gerigk L, Kauczor HU, Politi M, Essig M, Griffiths PD, Wilkinson ID.

Acta Radiol. 2009 Jun;50(5):521-30. doi: 10.1080/02841850902787685.

PMID:
19337867
18.

Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.

Rowley HA, Scialfa G, Gao PY, Maldjian JA, Hassell D, Kuhn MJ, Wippold FJ 2nd, Gallucci M, Bowen BC, Schmalfuss IM, Ruscalleda J, Bastianello S, Colosimo C.

AJNR Am J Neuroradiol. 2008 Oct;29(9):1684-91. doi: 10.3174/ajnr.A1185. Epub 2008 Jul 3.

19.

[Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers].

Essig M, Lodemann KP, LeHuu M, Schönberg SO, Hübener M, Van Kaick G.

Radiologe. 2002 Nov;42(11):909-15. German.

PMID:
12458444
20.

Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, Moeller A, Seeberg AH, Lodemann KP.

Radiology. 2004 Jan;230(1):55-64.

PMID:
14695387

Supplemental Content

Support Center